Impact of HIV impact on outcomes of deep-brain stimulation of the subthalamic nucleus for Parkinson's disease.
Details
Serval ID
serval:BIB_0C91CBFB5367
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Impact of HIV impact on outcomes of deep-brain stimulation of the subthalamic nucleus for Parkinson's disease.
Journal
European journal of neurology
ISSN
1468-1331 (Electronic)
ISSN-L
1351-5101
Publication state
Published
Issued date
04/2022
Peer-reviewed
Oui
Volume
29
Number
4
Pages
1232-1237
Language
english
Notes
Publication types: Journal Article
Publication Status: ppublish
Publication Status: ppublish
Abstract
Middle-aged persons living with HIV (PLHIV) have a heightened risk of more concomitant age-related comorbidities that are acknowledged as signs of poorer prognosis after deep-brain stimulation of the subthalamic nucleus (STN-DBS) at younger-than-expected ages. To assess the beneficial and adverse effects of STN-DBS in PLHIV with Parkinson's disease (PD).
We retrospectively included nine PLHIV with PD who had sustained virological control. Patients were followed up for 7 ± 4 years.
Patients' mean ages at PD onset and STN-DBS were 45 ± 15 and 53 ± 16 years, respectively. At STN-DBS, mean HIV infection and PD durations were 15 ± 12 and 8 ± 4 years, respectively. STN-DBS significantly improved 1-year Unified Parkinson's Disease Rating Scale (UPDRS)-III scores (71%), daily off-time (63%), motor fluctuations (75%) and daily levodopa-equivalent dose (68%); mean 5-year UPDRS-III score and motor fluctuation improvements remained ~45%. Impulse control disorders (affecting 6/9 patients) fully resolved after STN-DBS. Postoperative course was uneventful. No serious adverse events occurred during follow-up.
Our findings indicate that STN-DBS is a safe and effective treatment for PLHIV with PD.
We retrospectively included nine PLHIV with PD who had sustained virological control. Patients were followed up for 7 ± 4 years.
Patients' mean ages at PD onset and STN-DBS were 45 ± 15 and 53 ± 16 years, respectively. At STN-DBS, mean HIV infection and PD durations were 15 ± 12 and 8 ± 4 years, respectively. STN-DBS significantly improved 1-year Unified Parkinson's Disease Rating Scale (UPDRS)-III scores (71%), daily off-time (63%), motor fluctuations (75%) and daily levodopa-equivalent dose (68%); mean 5-year UPDRS-III score and motor fluctuation improvements remained ~45%. Impulse control disorders (affecting 6/9 patients) fully resolved after STN-DBS. Postoperative course was uneventful. No serious adverse events occurred during follow-up.
Our findings indicate that STN-DBS is a safe and effective treatment for PLHIV with PD.
Keywords
Adult, Aged, Deep Brain Stimulation/adverse effects, HIV Infections/complications, HIV Infections/therapy, Humans, Middle Aged, Parkinson Disease/drug therapy, Parkinson Disease/therapy, Retrospective Studies, Subthalamic Nucleus, Treatment Outcome, AIDS, HIV, Parkinson's disease, deep-brain stimulation, subthalamic nucleus
Pubmed
Web of science
Create date
17/04/2025 11:21
Last modification date
18/04/2025 7:05
Usage data
